Here’s what you need to know about BioAge’s IPO. BioAge Labs, Inc. is a clinical-stage biopharmaceutical firm based in ...

Earlier this week, BioAge said in a filing it was looking to offer 10.5M shares priced between $17 and $19 per share.The company also anticipated concurrently privately placing $10.6M of its ...

Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable private ...

BioAge Labs, Inc. ( (BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented ...

BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of shares on offer by 40%. The expansion of the listing reflects the massive ...

BioAge CEO and co-founder Kristen Fortney would own 6.7% of the company after the IPO. The offering would be the first Bay Area biotech IPO since February and only the fourth this year.

In that vein, there's a biotech stock called BioAge Labs (NASDAQ: BIOA) that just wrapped up its initial public offering (IPO) and is aiming to compete in the same areas as Lilly, as well as one ...

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

2024 Weight-loss drug developer BioAge raises $198 mln in U.S. IPO September 26, 2024 Obesity drug developer BioAge Labs aims up to $640 mln valuation in upsized US IPO September 25, 2024 Obesity ...